Dr. Reddy's Laboratories Limited (RDY) Analyst Estimates Quarterly

Dr. Reddy's Laboratories Limited

RDY (NYSE)

(%)

Financials
Dr. Reddy's Laboratories Limited Analyst Estimates Quarterly

Annual Quarterly

* (except for per share items) of USD

Period Ending:	2027 03-30	2025 12-30	2025 09-30	2025 06-30	2025 03-30	2024 12-30	2024 09-30	2024 06-30	2024 03-30	2023 12-30	2023 09-29	2023 06-29	2023 03-29	2022 12-29	2022 09-29	2022 06-29	2022 03-29	2021 12-29	2021 09-29	2021 06-29	2021 03-29	2020 12-29	2020 09-29	2020 06-29	2020 03-29	2019 12-29	2019 09-29	2019 06-29	2019 03-29	2013 12-29	2013 09-29	2013 06-29	2013 03-29	2012 12-29	2005 09-29	2005 06-29
Number of Analysts	1234	10	12	1	11	11	9	7	8	4	17	8	8	7	7	13	7	15	8	10	16	11	8	8	12	7	12	7	7	13	12	18	7	9	16	13
Estimated Revenue
Low	1234	79,878	82,776	82,565	79,650	77,243	73,156	69,470	67,245	66,555	63,549	60,983	58,501	56,744	54,192	51,250	49,171	52,201	49,462	48,226	45,988	47,635	44,945	39,848	40,940	39,878	40,299	38,672	37,246	1,283,076	1,612,666	1,585,888	1,290,580	1,549,613	188,280	226,771
Average	1234	83,914	86,959	86,737	83,674	81,145	76,853	72,980	70,643	69,169	67,878	63,794	61,198	59,359	56,690	53,612	51,438	54,608	51,742	50,449	48,108	49,831	47,017	41,684	42,828	41,717	42,156	40,454	38,963	1,603,844	2,015,832	1,982,361	1,613,225	1,937,016	235,350	283,464
High	1234	85,421	88,521	88,295	85,177	82,603	78,233	74,291	71,912	72,789	72,461	67,856	65,094	63,139	60,300	57,026	54,713	58,085	55,036	53,661	51,171	53,004	50,010	44,338	45,554	44,373	44,840	43,030	41,444	1,924,613	2,418,999	2,378,833	1,935,870	2,324,419	282,420	340,157
Estimated EBITDA
Low	1234	21,342	22,117	22,060	21,281	20,638	19,546	18,561	17,967	17,783	16,979	16,294	15,631	15,161	14,479	13,693	13,138	13,947	13,215	12,885	12,287	12,727	12,009	10,647	10,939	-128,068	10,767	10,333	9,952	392,678	313,839	334,303	372,182	338,036	39,143	32,045
Average	1234	22,421	23,234	23,175	22,357	21,681	20,534	19,499	18,875	18,481	18,136	17,045	16,351	15,860	15,147	14,324	13,744	14,590	13,825	13,479	12,854	13,314	12,562	11,138	11,443	-106,723	11,264	10,809	10,410	490,848	392,299	417,878	465,227	422,545	48,928	40,056
High	1234	22,823	23,651	23,591	22,758	22,070	20,903	19,850	19,214	19,448	19,361	18,130	17,392	16,870	16,111	15,236	14,619	15,519	14,705	14,337	13,672	14,162	13,362	11,847	12,172	-85,378	11,981	11,497	11,073	589,017	470,759	501,454	558,272	507,055	58,714	48,067
Estimated EBIT
Low	1234	16,876	17,489	17,444	16,828	16,320	15,456	14,677	14,207	14,062	13,426	12,884	12,360	11,989	11,450	10,828	10,389	11,029	10,450	10,189	9,716	10,064	9,496	8,419	8,650	-368,988	8,514	8,170	7,869	313,852	235,676	232,512	287,019	255,718	22,546	11,862
Average	1234	17,729	18,372	18,325	17,678	17,144	16,237	15,419	14,925	14,614	14,341	13,478	12,930	12,541	11,977	11,327	10,868	11,537	10,932	10,659	10,164	10,528	9,933	8,807	9,048	-307,490	8,907	8,547	8,232	392,315	294,595	290,640	358,774	319,647	28,183	14,828
High	1234	18,047	18,702	18,655	17,996	17,452	16,529	15,696	15,193	15,379	15,309	14,336	13,753	13,340	12,740	12,048	11,560	12,272	11,628	11,337	10,811	11,198	10,566	9,368	9,625	-245,992	9,474	9,091	8,756	470,778	353,514	348,768	430,528	383,577	33,819	17,793
Estimated Net Income
Low	1234	10,960	13,358	14,312	14,131	13,931	13,493	12,514	85,959	548,373	314,045	359,254	90,596	575,296	329,213	369,808	89,411	563,172	6,556	384,750	233,389	6,665	316,888	387,423	352,123	-358,174	513,131	174,333	3,553	224,569	221,074	201,239	220,635	204,553	28,866	14,096
Average	1234	11,691	14,249	15,267	15,073	14,860	14,393	13,348	107,449	685,466	392,556	449,068	113,245	719,119	411,516	462,260	111,764	703,965	6,954	480,938	291,737	7,070	396,110	484,278	440,154	-298,478	641,414	217,916	3,769	280,711	276,343	251,549	275,794	255,691	36,082	17,620
High	1234	11,964	14,582	15,623	15,425	15,207	14,729	13,660	128,939	822,559	471,068	538,881	135,894	862,943	493,819	554,712	134,116	844,758	7,530	577,125	350,084	7,655	475,332	581,134	528,184	-238,783	769,697	261,500	4,081	336,854	331,611	301,859	330,953	306,829	43,299	21,144
Estimated SGA Expenses
Low	1234	22,195	23,001	22,942	22,132	21,463	20,328	19,304	18,685	18,494	17,658	16,945	16,256	15,767	15,058	14,241	13,663	14,505	13,744	13,400	12,779	13,236	12,489	11,072	11,376	11,081	11,198	10,746	10,350	379,135	311,758	490,221	337,019	463,570	56,940	79,389
Average	1234	23,317	24,163	24,101	23,250	22,548	21,355	20,279	19,629	19,220	18,861	17,726	17,005	16,494	15,752	14,897	14,293	15,174	14,377	14,018	13,368	13,846	13,064	11,583	11,900	11,592	11,714	11,241	10,827	473,919	389,698	612,776	421,274	579,462	71,175	99,237
High	1234	23,736	24,597	24,534	23,668	22,953	21,739	20,643	19,982	20,226	20,135	18,855	18,088	17,544	16,755	15,846	15,203	16,140	15,293	14,911	14,219	14,728	13,896	12,320	12,658	12,330	12,460	11,957	11,516	568,703	467,637	735,332	505,529	695,354	85,410	119,084
Estimated EPS
Low	1234	13.16	16.04	17.18	16.96	16.72	16.2	15.02	13.78	12.37	12.27	11.9	8.91	10.44	8.67	7.61	7.28	8.95	7.87	7.67	7.09	8	6.84	5.97	6.29	5.59	6.76	5.09	4.27	16.45	14.88	23.97	20.65	29.75	1.77	2.61
Average	1234	14.03	17.11	18.33	18.09	17.84	17.28	16.02	14.7	14.66	14.52	12.63	9.46	11.07	9.2	8.07	7.73	9.5	8.35	8.14	7.52	8.49	7.26	6.33	6.67	5.93	7.18	5.4	4.52	20.42	18.6	29.96	26.08	37.18	2.65	3.04
High	1234	14.36	17.5	18.75	18.52	18.26	17.68	16.4	15.04	17.18	17.45	13.67	10.24	11.99	9.96	8.74	8.37	10.28	9.04	8.81	8.14	9.19	7.86	6.86	7.23	6.42	7.77	5.85	4.9	24.39	22.32	35.96	31.52	44.62	3.09	3.48

Market is Open

After-Hours Quote

Market is Open

After-Hours Quote

Dr. Reddy's Laboratories Limited Analyst Estimates Quarterly